plerixafor has been researched along with linagliptin in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
| Drucker, DJ; Fujishima, H; Fujita, H; Morii, T; Narita, T; Sato, T; Seino, Y; Shimizu, T; Takahashi, T; Takashima, S; Tsukiyama, K; Yamada, Y | 1 |
| Benetti, E; Klein, T; Miglio, G; Vitarelli, G | 1 |
3 other study(ies) available for plerixafor and linagliptin
| Article | Year |
|---|---|
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |
Stromal cell-derived factor-1 is upregulated by dipeptidyl peptidase-4 inhibition and has protective roles in progressive diabetic nephropathy.
Topics: Albuminuria; Animals; Benzylamines; Chemokine CXCL12; Cyclams; Diabetes Mellitus, Type 1; Diabetic Nephropathies; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Female; Fibrosis; Glomerular Filtration Rate; Glucagon-Like Peptide-1 Receptor; Heterocyclic Compounds; Humans; Hypoglycemic Agents; Kidney; Linagliptin; Liraglutide; Male; Mice; Mice, Inbred C57BL; Oxidative Stress; Receptors, CXCR4; Up-Regulation | 2016 |
Effects of linagliptin on human immortalized podocytes: a cellular system to study dipeptidyl-peptidase 4 inhibition.
Topics: Apoptosis; Benzylamines; Cell Line, Transformed; Cell Proliferation; Cyclams; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Heterocyclic Compounds; Humans; Linagliptin; Podocytes; Sitagliptin Phosphate | 2017 |